Clinical Trial Update: Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing changes in liver steatosis after switching HIV/HCV coinfected patients to raltegravir; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Juan Macías | Conditions: HCV Coinfection, HIV Infection | Phase 4 | Status: COMPLETED